Cognex Corporation filings document regulatory disclosures for an operating company focused on industrial machine vision products and automation technology. Its Form 8-K reports cover furnished operating results, quarterly cash dividends, share repurchase authorization, board and officer matters, annual meeting voting results, and changes in the company’s independent registered public accounting firm.
Proxy materials describe director elections, governance matters, executive compensation, shareholder voting procedures, and board committee oversight. The filing record also includes exhibit-based disclosures tied to financial-results releases and capital-return actions involving Cognex common stock.
Form 144 notice for Cognex Corp (CGNX): This filing notifies the proposed sale of 4,002 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $177,168.54. The shares represent restricted stock units acquired from the issuer on 02/22/2023 and the filer lists the approximate date of sale as 09/05/2025 on the NASDAQ. The filing reports no securities sold in the past three months for the account and includes the standard signature representation that the seller is not aware of undisclosed material adverse information.
Form 144 notice for Cognex Corp (CGNX) reports a proposed sale of 2,666 shares of Common Stock through broker Robert W Baird & Co., with an aggregate market value of $119,970 and approximate sale date of 09/05/2025 on NASDAQ. The filing shows the 2,666 shares were acquired through three Restricted Stock Unit releases on 02/21/2025, 02/22/2025 and 03/15/2025 totaling 2,666 shares, and fully settled upon vesting. The filing states there were no securities sold in the past three months by the reporting person. Filer contact and issuer identification fields in the notice are present but contain no specific names or CIK values in the provided content.
Matthew Moschner, CEO & President and a director of Cognex Corporation (CGNX), reported equity activity tied to restricted stock units that vested on 08/07/2025. A grant of 3,000 restricted stock units vested on that date, and 881 shares were withheld to satisfy tax-withholding obligations at a reported price of $41.36 per share. The Form 4 shows each RSU converts to one share and explains the vesting schedule for the grant (approximately 20%, 30% and 50% on the first three anniversaries of the grant date). The filing also details the reporting person’s outstanding stock option positions and other RSU balances, including a large option block of 279,070 options at a $27.99 strike, documenting the executive’s continuing equity holdings in the company.